Live
Funding 2 min read

LifeGlue raises EUR 705,000 seed round

Tampere University spin-out LifeGlue Technologies has raised EUR 705,000 in seed funding from Finnish business angels. The funding will facilitate the production of its tissue repair gel for laboratory use.

Image: Nordic Life Science

LifeGlue Technologies, a spin-out from Tampere University, has successfully raised EUR 705,000 in seed funding from business angels across Finland, Estonia, and Lithuania, with additional support from Innovestor. This funding is aimed at advancing the pharmaceutical-grade production of Glue4Life, a gel that helps cells grow and provides a structured environment in laboratory settings.

LifeGlue's production efforts will enable the development of its innovative materials for companies working in tissue engineering. The gel is made from hyaluronic acid, ensuring it meets Good Manufacturing Practice (GMP) standards needed for clinical trials. LifeGlue started commercial operations in December 2024 and is serving 15 paying customers in Europe, the US, and Australia.

The funding allows LifeGlue to scale up its production capabilities, positioning the company for significant entry into the tissue engineering and regenerative medicine markets.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

Nordic Life Science Open source

LifeGlue raises EUR 705,000 seed round

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

No reviewed connections found in the current history window.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority7 / 10

Priority

Source coverageSingle-source report

Single-source report

ConfidenceLimited

43 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • fresh coverage
  • editorial priority

Source monitoring: 100% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.